Catella, Stephanie
Gendreau, R. Michael
Kraus, Allison C.
Vega, Nicolette
Rosenbluth, Michael J.
Soefje, Sherry
Malhotra, Shishuka
Luciano, Juan V.
McCracken, Lance M.
Williams, David A.
Arnold, Lesley M.
Funding for this research was provided by:
Swing Therapeutics, Inc. (Swing Therapeutics, Inc.)
Article History
Received: 30 September 2022
Accepted: 22 May 2023
First Online: 29 June 2023
Declarations
:
: The study was performed in accordance with the Declaration of Helsinki and in compliance with Good Clinical Practice guidelines, applicable laws and regulatory requirements, and decisions made by the institutional review board that approved the study and oversaw the study sites (WCG IRB, Puyallup, WA).
: Informed consent was obtained from all participants included in the study.
: Not applicable.
: S.C. is a paid consultant of Swing Therapeutics, Inc. R.M.G. is a paid consultant of and shareholder in Swing Therapeutics, Inc. A.C.K., N.V., and M.J.R. are employees of and shareholders in Swing Therapeutics, Inc. S.S. and S.M. have no declared conflicts of interest. J.V.L., L.M.M., and D.A.W. are paid advisors of Swing Therapeutics, Inc. L.M.A. is an advisor for and has received research funding from Swing Therapeutics, Inc.